ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT01184300
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 200 participants
- Registry
-
NCT01184300
-
- Other papers using this trial's data
- Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT01184300. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2011-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation
- Acronym
- RAPID GENE
- Condition
- Stable Coronary Artery Disease
- Condition
- Acute Coronary Syndrome
- Condition
- Percutaneous Coronary Intervention
- Intervention (Genetic)
- Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Collaborator
- Spartan Bioscience Inc.
Record details
- Record id
cardio:ct-nct01184300- Content hash
c7cd8d24f05eb4d8736da336574cc8ddfc40d3cd2c04b0ebaa083cfa80e511eb